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The field of interventional cardiac procedures is rapidly 
growing. Since the “first in men” catheter-based implantation 
of a biological aortic valve by Cribier,1 the number of 
transcatheter based aortic replacements (TAVR) exceeds 
several thousand implantations per year worldwide. 
Beside this percutaneous treatment of mitral regurgitation 
(MitraClip®), closure of the left atrial appendage, and closure 
of a patent foramen ovale have been developed. Whereas 
MitraClip® procedures require general anaesthesia,2 
percutaneous closure of the left atrial appendage as well 
as closure of a patent foramen ovale are usually performed 
without the help of anaesthesiologists and will therefore not 
be discussed furthermore.
The transapical NeoChord DS 1000 system (NeoChord Inc, 
USA) is a new treatment option for patients with severe 
mitral regurgitation and prolapse of the posterior mitral 
leaflet that can be done off-pump.3
Transcatheter aortic valve replacement
TAVR is an alternative treatment option in high risk patients 
with severe symptomatic aortic stenosis where the local 
“heart team” considers the patient as unsuitable for 
conventional aortic valve replacement.4,5 The most common 
access routes for TAVR are transfemoral, transapical, and 
transaortic. Beside the Edwards SAPIEN and the Medtronic 
CoreValve, the most popular transcatheter valves, there 
are several other new valves currently under investigation 
like the Symetis Acurate valve (Symetis SA, Switzerland), 
JenaValve (JenaValve, Germany), the Engager Valve, the 
Sadra Lotus valve (Medtronic, USA), and the Direct Flow 
Medical (Direct Flow Medical , USA).6 
The incidence of vascular injuries as one of the most 
frequent complications for the transfemoral approach 
could be decreased due to smaller device sizes.7 Embolic 
protection devices like the Claret CE Pro system (Claret 
Medical Inc, USA) are designed to reduce the incidence 
of cerebrovascular events.8 But this has to be proven in 
ongoing studies.
The transfemoral TAVR is performed under analgo-sedation 
in some centres. TEE is helpful for guiding the TAVR procedure 
in patients in whom the transapical or transaortal approach 
is used. These patients obtain general anaesthesia. After 
induction of anaesthesia the first step of guiding the TAVR 
procedure is sizing of the aortic annulus (Figure 1). Real time 
3 dimensional transesophageal echocardiography (RT 3D 
TEE) adds additional information to 2D TEE.9 Annulus sizing 
is performed with X-plane at the midesophageal long axis 
view (ME LAX) and the midesophageal aortic valve short 
axis view (ME SAX). Measuring is performed in systole with 
trailing edge to leading edge convention at the hinge points 
of the leaflets (Figure 1A). Accurate assessment is necessary 
to prevent under- or overestimation. A too small valve leads 
to poor haemodynamics, paravalvular regurgitation or 
valvular migration. A too large valve in comparison may lead 
to incomplete deployment and annular rupture. The second 
step is to determine the distance of the coronary ostia to 
the aortic annulus. A distance of less than 10 mm indicates 
high risk of obstruction of the coronary arteries after valve 
implantation.10
The next step is guidewire positioning in the aortic valve. It 
must be ensured that the guidewire goes through the aortic 
valve without compromising the mitral valve apparatus 
including papillary muscles and chords. Correct placement 
is approved with TEE in ME LAX and ME SAX. Consecutively, 
a balloon valvuloplasty of the native aortic valve is 
performed (Figure 1B). The balloon should be located in 
central position and dilatation should be effective. Valve 
positioning and deployment of the valve prosthesis are 
guided with X-plane of the aortic valve in LAX and SAX view 
(Figure 1C). Postoperative functional control is performed 
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directly after implanting of the valve to make sure that the valve is 
fully deployed, to assess possible residual regurgitation 
(Figure 1D), to exclude persistent aortic stenosis, and to 
evaluate ventricular function. Colour flow Doppler and 
continuous wave Doppler are used.
Percutaneous MitraClip® Procedures
The MitraClip® procedure is a percutaneous transcatheter 
device that allows treatment of severe mitral regurgitation 
without the use of cardiopulmonary bypass. The principle 
is similar to the well known Alfieri-repair in conventional 
surgical mitral valve repair.11 The MitraClip® device 
is inserted through the femoral vein and via trans-
septal puncture introduced into the left atrium.12
According to the guidelines of the European Society 
of Cardiology and the European Association for 
Cardio-Thoracic Surgery the percutaneous mitral 
clip procedures may be considered in patients 
with symptomatic severe secondary mitral 
regurgitation despite optimal medical therapy, 
who are judged inoperable or at high surgical risk 
by a team of cardiologists and cardiac surgeon, 
and who have a life expectancy greater than one 
year.4 Echocardiographic guidance throughout 
the procedure is essential for the success of the 
procedure13 for (I) confirming the pathology, (II) 
graduation of mitral regurgitation during general 
anaesthesia (III) defining the trans-septal puncture 
site, (IV) guidance of the Clip implantation, 
and (V) evaluation of the repair. Optimal mitral 
valve morphology for this procedure is a central 
pathology in segment 2, no leaflet calcification, a 
mitral valve opening area > 4 cm2, mobile length 
of the posterior leaflet > 10 mm, coaptation depth 
< 11 mm, normal leaflet strength and mobility, and 
a flail-width < 15 mm.2 
Real time 3D transesophageal Echocardiography 
helps for orientation, guidance of the interventionalist 
and decreases the time for intervention.14 In the 
ACCESS trial the MitraClip® procedures has been 
effective with low rates of hospital mortality and 
adverse events.15
First step of guiding the MitraClip® procedures with 
3D TEE is the graduation of the mitral regurgitation 
and to display the position of the regurgitant jet 
origin (Figure 2A). A catheter is introduced in the 
femoral vein and proceeded up through the inferior 
vena cava into the right atrium. X-plane imaging 
starting from a modified midesophageal aortic valve 
SAX view indicates anterior and posterior direction 
on the left side and superior and inferior direction on 
the right side to define the optimal puncture site 
(Figure 2B). In the midesophageal four chamber view, 
the distance from the puncture site to the coaptation 
of both mitral valve leaflets is measured (Figure 2C). 
After positioning of the guidewire into the left upper 
pulmonary vein, the guide is introduced into the left atrium 
(Figure 2D, red arrow). To avoid damage of the left atrial wall 
after introducing the Clipdevice through the guide, enough 
distance of the guide to the left atrial wall should be present 
(Figure 2D, yellow arrow). 
The next important step is the alignment of the clip. The 
opened clip has to be oriented perpendicular to the free 
margin of the mitral valve leaflets to ensure optimal capture 
of both leaflets (Figure 3A). After introducing the clip into 
the left ventricle, it has to be positioned over the origin of 
the mitral regurgitant jet. At this time the echocardiograph 
Figure 1: Important steps in TAVR: A: Annulus sizing using X-Plane, B: Central positioning 
of the guidewire, C: Positioning of the valve, D: Severe paravalular leackage after 
implantation 
Figure 2: Echoguidance during MitraClip® procedure. A: localisation of the origin of the 
mitral regurgitation using X- plane Color Doppler imaging starting from the midesophageal 
mitral commissural position. B: Guidance of the transseptal puncture using X-plane starting 
from a modified midesophageal Aortic Valve SAX view. On the left picture the anterior (ant) 
and posterior (post) part of the right atrium is displayed, on the right picture the superior 
(sup) and inferior (inf) part. C: Measurement of the distance between transseptal puncture 
and coaptation of the mitral valve leaflets in the midesophageal four chamber view. 
A distance of 4.5 ± 0.5 cm should be achieved. D: Visualisation of the guide in the left 
atrium with enough distance to the left atrial wall.
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and the interventionalist have to work precisely. The 
echocardiographer guides the interventionalist to get the 
optimal position of the clip. For this step again X- plane 
imaging is very helpful starting from a midesophageal 
mitral commissural view (Figure 3B). If the optimal position 
was found then the midesophageal long axis is required 
to see if the gripper grasp the tips of the anterior and 
posterior mitral leaflet (Figure 3C). Leaflet insertion has to 
be controlled to ensure that both leaflets were grasped 
securely before the Clip is released (Figure 3D). 
Optimal outcome is achieved if the regurgitant jet 
is two grade smaller than prior the procedure and 
the resulting transmitral mean pressure gradient is 
< 6 mm. 
NeoChord® Implantation 
The NeoChord® DS1000 system (NeoChord Inc, 
USA) allows implantation of artificial neochordae to 
fix a well defined prolapse of the mitral valve leaflet 
without the use of a cardiopulmonary bypass.3 In 
this procedure RT 3D TEE is also crucial to guide 
the intervention and to control the success of the 
procedure. With a left lateral minithoracotomy the 
NeoChord® system gets introduced to the apex 
of the heart. The NeoChord® DS 1000 System is 
inserted through the apex of the heart into the left 
ventricle. From this position the mitral valve leaflets 
can be reached and fixed with the NeoChord® 
system. The prolapsing leaflet is grasped with 
the device guided by TEE. If the leaflet has been 
captured appropriately, a suture is attached to 
the leaflet. With the use of TEE the length of the 
suture is determined by observing the improvement 
of mitral valve regurgitation. After confirmation with TEE 
of reduction of the prolapse of the mitral valve leaflet the 
suture is fixed at the apex. 
It has been shown that offpump transapical implantation of 
artificial chordae to correct mitral regurgitation is technically 
safe and feasible, however, it yields further potential for 
improvement of efficacy.16
Figure 3: Echoguidance during MitraClip® procedure. A: Correct alignment of the clip 
in Real Time 3 D wide sector mode. B: Orientation for correct positioning of the clip in 
X-plane starting from midesophageal mitral commissural view with medial (med) and 
lateral (lat) part of the mitral valve on the left picture and posterior (post) and anterior (ant) 
part on the right picture. C: “Gripper down” in the midesophageal long axis view. Both 
leaflets can be seen in- between the grippers (arrows). D: Control of leaflet insertion after 
grasping the leaflets to ensure that enough tissue was catched (arrow). 
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